Clinical Trial Update: Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating gadobutrol (Gadavist) enhanced CMRI for detecting coronary artery disease has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Gadavist (gadobutrol)

Snippet

Sponsor: Bayer | Conditions: Coronary Artery Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-05-16